PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING (PBPK) OF PITAVASTATIN AND ATORVASTATIN TO PREDICT DRUG-DRUG INTERACTIONS (DDIS).

被引：0
|
作者：
Duan, P. [1 ]
Zhao, P. [2 ]
Zhang, L. [2 ]
机构：
[1] US FDA, Silver Spring, MD USA
[2] US FDA, Off Clin Pharmacol, Off Translat Sci, CDER, Silver Spring, MD USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2015年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PT-17
引用
收藏
页码：S16 / S17
页数：2
相关论文
共 50 条
  • [21] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING FOR ASSESSMENT OF THE DRUG-DRUG INTERACTION POTENTIAL OF ZAVEGEPANT
    Ke, A.
    Callegari, E.
    Bhardwaj, R.
    Varma, M.
    Muto, C.
    Bertz, R.
    Sahasrabudhe, V.
    Liu, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S107 - S107
  • [22] Application of Physiologically-Based Pharmacokinetic Modeling to Predict Gastric pH-Dependent Drug-Drug Interactions for Weak Base Drugs
    Dong, Zhongqi
    Li, Jia
    Wu, Fang
    Zhao, Ping
    Lee, Sue-Chih
    Zhang, Lillian
    Seo, Paul
    Zhang, Lei
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2020, 9 (08): : 456 - 465
  • [23] A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL FOR SIMULATION OF NALOXEGOL PHARMACOKINETICS AND DRUG-DRUG INTERACTION (DDI) POTENTIAL
    Zhou, D.
    Bui, K.
    Sostek, M.
    Al-Huniti, N.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S53 - S53
  • [24] LEVERAGING PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING AND CLINICAL DATA TO PREDICT DRUG-DRUG INTERACTIONS (DDI) OF AVAPRITINIB AND GUIDE DOSE ADJUSTMENTS
    Suram, A.
    Powers, J.
    Dave, N.
    Kim, S.
    Baker, J.
    Ankrom, W.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S106 - S106
  • [25] Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions
    Nina Hanke
    José David Gómez-Mantilla
    Naoki Ishiguro
    Peter Stopfer
    Valerie Nock
    Pharmaceutical Research, 2021, 38 : 1645 - 1661
  • [26] Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions
    Hanke, Nina
    Gomez-Mantilla, Jose David
    Ishiguro, Naoki
    Stopfer, Peter
    Nock, Valerie
    PHARMACEUTICAL RESEARCH, 2021, 38 (10) : 1645 - 1661
  • [27] PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING OF DRUG-DRUG INTERACTION (DDI) BETWEEN TEMSIROLIMUS AND ITS METABOLITE SIROLIMUS WITH MIDAZOLAM.
    Lin, J.
    Loi, C. -M.
    Tse, S.
    Boni, J.
    Shetty, B. V.
    Goosen, T. C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S37 - S37
  • [28] Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example
    Chen, Yuan
    Zhu, Rui
    Ma, Fang
    Mao, Jialin
    Chen, Eugene C.
    Choo, Edna F.
    Sahasranaman, Srikumar
    Liu, Lichuan
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2018, 39 (09) : 420 - 430
  • [29] Use of physiologically based pharmacokinetic modeling for assessment of drug-drug interactions
    Baneyx, Guillaume
    Fukushima, Yumi
    Parrott, Neil
    FUTURE MEDICINAL CHEMISTRY, 2012, 4 (05) : 681 - 693
  • [30] A physiologically-based pharmacokinetic precision dosing approach to manage dasatinib drug-drug interactions
    Kovar, Christina
    Loer, Helena Leonie Hanae
    Ruedesheim, Simeon
    Fuhr, Laura Maria
    Marok, Fatima Zahra
    Selzer, Dominik
    Schwab, Matthias
    Lehr, Thorsten
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (07): : 1144 - 1159
12345